Moleculin Biotech, Inc. (MBRX)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Apr. 10, 2026 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-3, originally filed on March 27, 2026. They a… | Read Filing EDGAR |
| Apr. 2, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Moleculin Biotech, Inc. that it will not review the company's registration statement filed on March 27, 2026. The letter emphasizes the company's respo… | Read Filing EDGAR |
| Jan. 2, 2026 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking for it to be declared eff… | Read Filing EDGAR |
| Jan. 2, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Moleculin Biotech, Inc. that it will not review their registration statement filed on December 23, 2025. The letter emphasizes the company's responsibi… | Read Filing EDGAR |
| Sep. 29, 2025 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-3. They are seeking to have it declared effec… | Read Filing EDGAR |
| Sep. 24, 2025 | UPLOAD | Neutral/Informational | Low | The SEC correspondence dated September 24, 2025, informs Walter Klemp, CEO of Moleculin Biotech, Inc., that the SEC will not review their registration statement filed on September… | Read Filing EDGAR |
| Jun. 17, 2025 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request for the acceleration of the effective date of its registration statement on Form S-1. Roth Capital Partners, LLC, acting as the pla… | Read Filing EDGAR |
| Jun. 17, 2025 | CORRESP | Neutral/Informational | High | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking to have the registration … | Read Filing EDGAR |
| Jun. 16, 2025 | CORRESP | Concern from SEC | Moderate | Moleculin Biotech, Inc. submitted a response to the SEC's comment letter regarding their Amendment No. 2 to Registration Statement on Form S-1. The SEC raised concerns about poten… | Read Filing EDGAR |
| Jun. 13, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Moleculin Biotech, Inc.'s amended registration statement and provided several comments requiring further clarification and additional risk disclosures. Key co… | Read Filing EDGAR |
| Jun. 11, 2025 | CORRESP | Concern from SEC | Moderate | Moleculin Biotech, Inc. submitted a response to the SEC's comment letter regarding their Amendment No. 1 to Registration Statement on Form S-1. The SEC raised concerns about the p… | Read Filing EDGAR |
| Jun. 10, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed Moleculin Biotech, Inc.'s amended registration statement and has issued comments requiring further clarification and additional disclosures. Specifically, the… | Read Filing EDGAR |
| Jun. 3, 2025 | CORRESP | Neutral/Informational | High | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking to have it declared effec… | Read Filing EDGAR |
| Jun. 3, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from Roth Capital Partners, LLC, acting as the placement agent for Moleculin Biotech, Inc., requests the acceleration of the effective date for the company's re… | Read Filing EDGAR |